Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:FOLD NASDAQ:LGND NASDAQ:RGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$8.61-1.0%$9.92$6.02▼$11.31$1.80B1.043.04 million shs3.10 million shsFOLDAmicus Therapeutics$5.96-5.2%$6.07$5.51▼$12.65$1.84B0.513.25 million shs5.16 million shsLGNDLigand Pharmaceuticals$139.10+1.1%$112.10$90.29▼$139.71$2.68B0.84119,529 shs347,058 shsRGLSRegulus Therapeutics$8.16$8.07$0.83▼$8.35$564.92M0.351.01 million shsN/AA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%-1.71%-13.55%+16.35%+18.43%FOLDAmicus Therapeutics0.00%-2.13%+4.01%-12.74%-43.77%LGNDLigand Pharmaceuticals0.00%+14.30%+21.34%+32.51%+37.63%RGLSRegulus Therapeutics0.00%0.00%-0.61%+296.12%+380.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCRXBioCryst Pharmaceuticals4.529 of 5 stars4.51.00.04.23.91.70.6FOLDAmicus Therapeutics4.138 of 5 stars3.41.00.04.33.30.01.9LGNDLigand Pharmaceuticals3.6705 of 5 stars1.51.00.04.42.83.31.9RGLSRegulus Therapeutics1.7065 of 5 stars2.15.00.00.00.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.7093.96% UpsideFOLDAmicus Therapeutics 2.80Moderate Buy$16.22172.18% UpsideLGNDLigand Pharmaceuticals 3.00Buy$147.175.80% UpsideRGLSRegulus Therapeutics 2.29Hold$8.504.17% UpsideCurrent Analyst Ratings BreakdownLatest RGLS, LGND, FOLD, and BCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025FOLDAmicus TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight7/1/2025BCRXBioCryst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $15.006/30/2025BCRXBioCryst PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.006/30/2025BCRXBioCryst PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.006/25/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.005/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/7/2025BCRXBioCryst PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.005/6/2025BCRXBioCryst PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $17.005/6/2025BCRXBioCryst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M4.00N/AN/A($2.30) per share-3.74FOLDAmicus Therapeutics$528.29M3.47N/AN/A$0.65 per share9.17LGNDLigand Pharmaceuticals$167.13M16.05$1.61 per share86.57$43.95 per share3.16RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.26N/AN/A1.41-10.62%N/A-11.06%8/4/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.09N/A13.86N/A-5.41%4.67%1.05%8/14/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A37.49N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)Latest RGLS, LGND, FOLD, and BCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FOLDAmicus Therapeutics$0.01N/AN/AN/AN/AN/A8/14/2025Q2 2025RGLSRegulus Therapeutics-$0.23N/AN/AN/AN/AN/A8/5/2025Q2 2025LGNDLigand Pharmaceuticals$1.54N/AN/AN/A$43.87 millionN/A8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.02N/AN/AN/A$149.59 millionN/A5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.932.88FOLDAmicus Therapeutics2.023.342.47LGNDLigand PharmaceuticalsN/A5.275.02RGLSRegulus TherapeuticsN/A16.3116.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%FOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals4.80%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals7.00%RGLSRegulus Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.25 million199.21 millionOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableRGLS, LGND, FOLD, and BCRX HeadlinesRecent News About These CompaniesRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives $8.50 Average PT from BrokeragesJuly 17 at 2:03 AM | americanbankingnews.comNovartis (NVS) Acquires Regulus Therapeutics for $1.7 BillionJune 28, 2025 | finance.yahoo.comRegulus Therapeutics (NASDAQ:RGLS) Upgraded at Wall Street ZenJune 27, 2025 | marketbeat.comNovartis concludes acquisition of Regulus TherapeuticsJune 26, 2025 | medicaldialogues.inMNovartis concludes Regulus Therapeutics acquisitionJune 26, 2025 | pharmaceutical-technology.comPPress Release: Novartis completes acquisition of Regulus TherapeuticsJune 25, 2025 | finanzen.atFNovartis completes acquisition of Regulus TherapeuticsJune 25, 2025 | globenewswire.comNovartis announces expiration of HSR waiting period of Regulus Therapeutics tender offerJune 24, 2025 | pharmabiz.comPRegulus Therapeutics Inc.June 21, 2025 | barrons.comRegulus Therapeutics (NASDAQ:RGLS) Sees Large Volume Increase - What's Next?June 20, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Acquires 12,000 SharesJune 5, 2025 | insidertrades.comInsider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS)June 4, 2025 | gurufocus.comRegulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 PayoutJune 4, 2025 | seekingalpha.comNovartis commences tender offer to acquire Regulus TherapeuticsMay 29, 2025 | pharmabiz.comPNovartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing showsMay 29, 2025 | fiercepharma.comFNovartis arm commences tender offer to buy Regulus TherapeuticsMay 28, 2025 | medicaldialogues.inMLatham and Covington Advise on Novartis’s Acquisition of RegulusMay 16, 2025 | lawstreetmedia.comLRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 9, 2025 | finanznachrichten.deRegulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 8, 2025 | prnewswire.comREGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLSMay 4, 2025 | businesswire.comNovartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion DealMay 4, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 High-Risk, High-Reward Stocks With Explosive UpsideBy Nathan Reiff | July 16, 2025View 3 High-Risk, High-Reward Stocks With Explosive UpsideRGLS, LGND, FOLD, and BCRX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$8.61 -0.09 (-1.03%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$8.61 0.00 (0.00%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Amicus Therapeutics NASDAQ:FOLD$5.96 -0.33 (-5.25%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.98 +0.02 (+0.40%) As of 07/18/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$139.10 +1.53 (+1.11%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$139.14 +0.04 (+0.03%) As of 07/18/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Regulus Therapeutics NASDAQ:RGLS$8.16 0.00 (0.00%) As of 06/25/2025Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
